Cytovance Biologics, an Oklahoma City-based full service contract manufacturer of mammalian and microbial biologics for biotechnology and pharmaceutical companies, has raised $22.5m in equity financing.
Investors include Great Point Partners, LLC.
Cytovance specializes in the production of therapeutic proteins and monoclonal antibodies from mammalian and microbial cell cultures. The company also offers process development, cGMP cell banking, in-house analytical development and testing and a full complement of client support services.
Led by Darren Head, Cytovance intends to use the funds to expand its manufacturing facility, service and staff. The company will move from 840 Research Parkway to 800 Research Parkway to occupy the state-of-the-art laboratories left by Genzyme in December 2010.
In conjunction with the investment, Great Point Managing Directors Dr. Jeffrey R. Jay and David Kroin, and Senior Vice President Noah F. Rhodes, III will join Cytovance’s Board.